



Joe Lombardo
Governor

NEVADA HEALTH AUTHORITY

Nevada Medicaid
4070 Silver Sage Drive
Carson City, NV 89701
NVHA.NV.GOV



Stacie Weeks, Director
Ann Jensen, Administrator

Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, September 18, 2025, at 1:00 PM

Name of Organization: The State of Nevada, Nevada Health Authority, Nevada Medicaid, Silver State Scripts Board.

Agenda Item	Record	Notes																								
1. Closed Executive Session																										
A. Call to Order and Roll Call	<p>Chairperson Mark Decerbo called the meeting to order at 1:02 PM on September 18, 2025.</p> <p>Chairperson Decerbo took the roll.</p> <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm. D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>Nevada Medicaid Staff Present were as follows:</p> <ul style="list-style-type: none"> • Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director • Brown, Antonio, Chief of Pharmacy & DMEPOS • Palomino, Bonnie, Pharmacy Services Manager • Flowers, Ellen, Social Services Program Specialist II • Lithier, Gabriel, Senior Deputy Attorney General (SDAG) <p>Prime Staff Present were as follows:</p> <ul style="list-style-type: none"> • Deoliveira, Brittany, Pharm.D., Clinical Account Manager
	Present	Absent																								
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								

		<ul style="list-style-type: none"> • Czechowski, Jessica, Pharm.D., Director, Clinical Account Services • Martinez, Chris, Sr. Business Analyst • Rivas, Melissa, Sr. Business Analyst
B. Financial Review of Drug Classes with Proposed Changes	<p>Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with the Financial Review of Drug classes with proposed changes up for review.</p> <p>Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.</p> <p>Dr. Deoliveira presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Anticonvulsants • Atypical Antipsychotics – Oral/Topical • Topical Antivirals • Bladder Antispasmodics • Rapid-Acting Insulins • Pre-Mixed Insulin Combinations • Bile Acid Sequestrants • Narcolepsy Agents • Ophthalmic Corticosteroids • Platelet Inhibitors • Anxiolytics, Sedatives, and Hypnotics • Gastrointestinal Anti-inflammatory Agents • Functional Gastrointestinal Disorder Drugs • Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products 	

	<ul style="list-style-type: none"> Topical Retinoids <p>Dr. Deoliveira presented the financial review of the new drug classes being reviewed for proposed addition:</p> <ul style="list-style-type: none"> Functional Gastrointestinal Disorder Drugs: Diarrhea-Predominant 																									
2. Open Public Meeting																										
A. Call to Order and Roll Call	<p>Chairperson Decerbo called the meeting to order at 2:05 PM on September 18, 2025.</p> <p>A quorum was present.</p> <p>Chairperson Decerbo took the roll.</p> <table> <thead> <tr> <th></th><th>Present</th><th>Absent</th></tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </tbody> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none"> Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director Brown, Antonio, Chief of Pharmacy & DMEPOS Palomino, Bonnie, Pharmacy Services Manager Flowers, Ellen, Social Services Program Specialist II Lither, Gabriel, Senior Deputy Attorney General (SDAG) <p>Prime Staff Present were as follows:</p> <ul style="list-style-type: none"> Deoliveira, Brittany, Pharm.D., Clinical Account Manager Czechowski, Jessica, Pharm.D., Director, Clinical Account Services Martinez, Chris, Sr. Business Analyst Rivas, Melissa, Sr. Business Analyst <p>The public attendee list is included</p>
	Present	Absent																								
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								

		as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.																																
B. Approval for previous Meeting Minutes from June 12, 2025.	<p>Board Member Sapandeep Khurana moved to approve the meeting minutes and Board Member Elizabeth Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
C. Public Comments	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																	
D. Status Update by NVHA	<p>Chief of Pharmacy Services, Antonio Brown, provided an announcement.</p> <ul style="list-style-type: none">First, as many of you know, we have officially transitioned to the Nevada Health Authority under the Division of Nevada Medicaid. We are no longer operating under DHCFP. While the name has changed, our mission remains the same and there are no changes to this board.																																	

	<p>We remain committed to strengthening our work and continuing to improve the impact we make together.</p> <ul style="list-style-type: none"> • Next, I'd like to just take a moment to recognize and say farewell to one of our valued board members, Dr. Ward. Dr. Ward began serving in 2017 with the Pharmacy and Therapeutics Committee, and has been with Silver State Scripts Board since its creation in 2019. Over the years, she has brought a wealth of clinical insight, thoughtful perspective and unwavering dedication to our work. Her contribution has been instrumental in shaping the direction and success of this board, and her presence will be deeply missed. On behalf of Nevada Medicaid and the many individuals and families we serve, we extend our heartfelt thanks to Dr. Ward. We wish her all the best in her future endeavors and hope she continues making meaningful impacts in whatever her path leads. • Finally, as always, I'd like to remind everyone that we are actively recruiting practicing pharmacists and physicians to serve on our board. If you or someone you know may be interested, please do not hesitate to reach out to rxinfo@nvha.nv.org Thank you again for being here today and for continued commitment to the health and well-being of Nevada. 	
3. Clinical Presentations		
A. For Possible Action: Discussion and possible adoption of Anticonvulsants.		
i. Public comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Herbert Peoples, Medical Outcomes Liaison for UCB.</p>	

ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Joseph Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime, and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"> • Keeping the carbamazepine products as preferred, moving Tegretol and Carbatrol from preferred to non-preferred, and placing Equetro as non-preferred. • Keeping the divalproex generic products as preferred and moving the branded Depakote products from preferred to non-preferred. • Keeping the generic ethosuximide product as preferred and moving the brand Zarontin from preferred to non-preferred. • Keeping the brand Felbatol product as preferred and moving the generic felbamate to non-preferred. • Keeping lamotrigine tablets, dispersible tablets, oral disintegrating tablets (ODT) and XR formulations as preferred; and moving the Lamictal brand tablets, dispersible tablets, and oral disintegrating tablets (ODT) to non-preferred. 																																	

	<ul style="list-style-type: none">• Moving lamotrigine dose pack and ODT dose pack from non-preferred to preferred; and moving Lamictal dose packs from preferred to non-preferred.• Keeping Celontin as preferred, as placing methsuximide generic product as non-preferred.• Placing the generic perampanel product as preferred and moving Fycompa branded formulations to non-preferred.• Removing the obsolete product Gabitril from the PDL and placing its generic product tiagabine as non-preferred.• Removing Qudexy XR from the PDL due to product discontinuation.• Defining the preferred strengths of topiramate sprinkle as the 15 mg and 25 mg, and non-preferring the topiramate sprinkle 50 mg strength.• And lastly, removing Depakene from the PDL due product discontinuation.																									
v. Board Member Comments	<p>Comment was provided by Board Member Khurana.</p> <p>Comment was provided by Board Member Adashek.</p>																									
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Leana Ramirez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

	<ul style="list-style-type: none">• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>									
B. For Possible Action: Discussion and possible adoption of Atypical Antipsychotics – Oral/Topical.										
i. Public comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Aaron Fayer, HUR Field Scientist at Bristol-Myers Squibb.</p> <p>Public comment was provided by Amy Hale, Pharmacist and Principal Scientific Account Lead with Johnson & Johnson Innovative Medicine.</p>									
ii. Drug class review presentation by Prime.	<p>Dr. Deoliveira discussed Cobenfy. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.							
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>							

	<ul style="list-style-type: none">• Joseph Adashek, MD• Mark Crumby, Pharm.D.• Elizabeth Gonzalez, Pharm.D.• Sapandeep Khurana, MD• Leana Ramirez, Pharm.D.• Aditi Singh, MD	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>	
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none">• Moving Saphris from preferred to non-preferred, and instead preferring the generic asenapine• Moving Fanapt from preferred to non-preferred• Placing Cobenfy as non-preferred• Removing Fazaclo from the PDL due to product discontinuation		
v. Board Member Comments	Comment was provided by Board Member Khurana. Comment was provided by Board Member Adashek. Comment was provided by Board Member Gonzalez.		
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairperson Decerbo moved to approve the proposed changes as presented by Prime with the exception of placing Cobenfy as preferred instead of non-preferred, and Board Member Adashek seconded the motion. <div><div><div></div><div>Yes</div><div>No</div><div>Abst.</div></div><div><div><ul style="list-style-type: none">• Mark Decerbo, Pharm.D., Chair• Joseph Adashek, MD• Mark Crumby, Pharm.D.• Elizabeth Gonzalez, Pharm.D.• Sapandeep Khurana, MD• Leana Ramirez, Pharm.D.• Aditi Singh, MD</div><div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div></div></div>		

C. For Possible Action: Discussion and possible adoption of Topical Antivirals.																																		
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none">Two drugs in this class (Xerese cream and Zovirax cream/oointment) are no longer participating in the MDRP as of 10/1/2025 and therefore will be removed from the PDLPrime recommends no further changes at this time																																	

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
D. For Possible Action: Discussion and possible adoption of Bladder Antispasmodics.																																		
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Jeff Nesheim from Sumitomo Pharma America in the Medical Affairs Group.</p>																																	
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																																	

		<div> <div></div> <div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> </div> <ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"> • Keeping Detrol and Detrol LA preferred until supply exhausts (as it has been confirmed to be discontinued), and moving its generic tolterodine (both the IR and ER formulations) from non-preferred to preferred • Moving the brand Toviaz from preferred to non-preferred, and placing the generic product fesoterodine ER as preferred • Keeping the oxybutynin IR 5 mg tablet as preferred, and defining the oxybutynin IR 2.5 mg tablet as non-preferred • Moving the brand Myrbetriq ER tablets from non-preferred to preferred, keeping the Myrbetriq granules as non-preferred, and placing the generic mirabegron ER tab as non-preferred • And lastly, removing the discontinued products: Ditropan XL, Gelnique, and Sanctura. 	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div> <div></div> <div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> </div> <ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	

	<ul style="list-style-type: none">• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																	
E. For Possible Action: Discussion and possible adoption of Rapid-Acting Insulins.																																		
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															

iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none">Moving brand Novolog from non-preferred to preferred																																	
v. Board Member Comments	Comment was provided by Board Member Khurana.																																	
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
F. For Possible Action: Discussion and possible adoption of Pre-Mixed Insulin Combinations.																																		
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	

iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<div>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Prime and Board Member Gonzalez seconded the motion.</div> <div>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
iv.	Presentation of recommendations for PDL inclusion by Prime.	<div>Dr. Deoliveira recommended:</div> <div>• Moving brand Novolin 70/30 and Novolog 70/30 from non-preferred to preferred.</div>																																
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<div>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</div> <div>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>								
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

	<ul style="list-style-type: none">• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																	
G. For Possible Action: Discussion and possible adoption of Bile Acid Sequestrants.																																		
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none">• Moving brand Welchol from preferred to non-preferred and instead																																	

	preferring the generic colesevalam.																																	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
H. For Possible Action: Discussion and possible adoption of Narcolepsy Agents.																																		
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																									
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

	<ul style="list-style-type: none">• Joseph Adashek, MD• Mark Crumby, Pharm.D.• Elizabeth Gonzalez, Pharm.D.• Sapandeep Khurana, MD• Leana Ramirez, Pharm.D.• Aditi Singh, MD	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>																																
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none">• Moving Nuvigil from preferred to non-preferred and instead preferring the generic armodafinil.• And placing the generic for Xyrem (sodium oxybate solution) as non-preferred.																																	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
I. For Possible Action: Discussion and possible adoption of Ophthalmic Corticosteroids.																																		
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	

ii.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalaz seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"> • Moving the prednisolone generic product from non-preferred to preferred. • Removing Omnipred from the PDL, as this product has been discontinued. 																																	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																	
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																

	<ul style="list-style-type: none">Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																	
J. For Possible Action: Discussion and possible adoption of Platelet Inhibitors.																																		
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															

iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"> • Durlaza will be removed from the PDL as this product is no longer participating in the MDRP • Removing brand Aggrenox from the PDL, as this product has been discontinued and moving its generic (aspirin/dipyridamole) from non-preferred to preferred. • Placing ticagrelor (the generic for Brilinta) as non-preferred 																																	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																
K.	For Possible Action: Discussion and possible adoption of Anxiolytics, Sedatives, and Hypnotics.																																		
i.	Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	

iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<div>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Adashek seconded the motion.</div> <div>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
iv.	Presentation of recommendations for PDL inclusion by Prime.	<div>Dr. Deoliveira recommended:</div> <ul style="list-style-type: none">• Moving brand Rozerem from preferred to non-preferred, and placing its generic ramelteon as preferred• Keeping temazepam 7.5 mg, 15 mg, and 30 mg strengths as preferred, and non-prefering the temazepam 22.5 mg strength• Moving sublingual zolpidem from preferred to non-preferred• Defining the zolpidem capsule product as non-preferred• Moving zolpidem CR from non-preferred to preferred• Moving flurazepam from preferred to non-preferred• Moving eszopiclone (the generic for Lunesta) from non-preferred to preferred• Removing Sonata and Zolpimist from the PDL, as these products have been discontinued																																

v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																
L.	For Possible Action: Discussion and possible adoption of Gastrointestinal Anti-Inflammatory Agents.																																		
i.	Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
ii.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody></tbody></table>		Yes	No	Abst.																													
	Yes	No	Abst.																																

	<ul style="list-style-type: none">• Mark Decerbo, Pharm.D., Chair• Joseph Adashek, MD• Mark Crumby, Pharm.D.• Elizabeth Gonzalez, Pharm.D.• Sapandeep Khurana, MD• Leana Ramirez, Pharm.D.• Aditi Singh, MD	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>		
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends:</p> <ul style="list-style-type: none">• Apriso and Colazal will be removed from the PDL as they are no longer participating in the MDRP• Moving mesalamine (the generic for Apriso) from non-preferred to preferred• Moving mesalamine (the generic for Lialda) from non-preferred to preferred• Moving Pentasa from preferred to non-preferred, and defining its generic mesalamine product as non-preferred as well• Removing Delzicol from the PDL, as this product has been discontinued• Moving brand Canasa suppository from preferred to non-preferred, and instead preferring mesalamine suppository (the generic for Canasa)			
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div></div></div></div></div></div>	<div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div></div></div></div></div></div>	<div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div></div></div></div></div></div>	

	<ul style="list-style-type: none">• Sapandeep Khurana, MD• Leana Ramirez, Pharm.D.• Aditi Singh, MD	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>																																	
M. For Possible Action: Discussion and possible adoption of Functional Gastrointestinal Disorder Drugs.																																			
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																		
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																		
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>		
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommends: <ul style="list-style-type: none">• Relistor, Trulance, and Zelnorm will be removed from the PDL as they are no longer participating in the MDRP.																																		

	<ul style="list-style-type: none">• Adding “constipation-related” to this class name on the PDL to differentiate it from the diarrhea-predominant drugs.• Placing prucalopride (the generic for Motegrity) as non-preferred.																																	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
N. For Possible Action: Discussion and possible adoption of Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products.																																		
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.																																	

clinical/therapeutic equivalency of agents in class.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends:</p> <ul style="list-style-type: none">• Acanya, Azelex, Amzeeq, and Onexton will be removed from the PDL as they are no longer participating in the MDRP.• Placing clindamycin/benzoyl peroxide (the generic for Duac) as preferred, keeping all other clindamycin/benzoyl peroxide gel formulations as non-preferred.• Removing Duac CS from the non-preferred drug list, as this product has been discontinued.																																	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

	<ul style="list-style-type: none">• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																	
O. For Possible Action: Discussion and possible adoption of Topical Retinoids.																																		
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
ii. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															

iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends:</p> <ul style="list-style-type: none">• Retin-A, Ziana, and Arazlo will be removed from the PDL as they are no longer participating in the MDRP.• Placing tretinoin cream as a preferred agent.• Placing tretinoin gel (the generic for Avita and Retin-A) as preferred and placing tretinoin gel (the generic for Atralin) as non-preferred.• Defining the tretinoin microspheres gel products as non-preferred (no change, just clarifying due to some tretinoin products shifting positions in this class).• Placing clindamycin/tretinoin combination product as non-preferred.• Placing Twynéo (the brand only combination product of tretinoin and benzoyl peroxide) as non-preferred.• Removing Avita from the PDL, as this product has been discontinued.																																	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																
P.	New Drug Class Being Reviewed for Proposed Addition: Functional Gastrointestinal Disorder																																		

Drugs: Diarrhea-Predominant.																																		
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
ii. Drug class review presentation by Prime	Dr. Deoliveira discussed Lotronex, Viberzi and Xifaxan. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies. Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
iv. Presentation of recommendations for PDL inclusion by Prime	Dr. Deoliveira recommends: <ul style="list-style-type: none">• Lotronex and Viberzi be placed as preferred.• Alosetron (the generic for Lotronex) be placed as non-preferred.																																	

<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
<p>Q. Annual Review: Established Drug Classes without Proposed Changes.</p>	<ul style="list-style-type: none">• Analgesics: Miscellaneous Analgesics, Neuropathic Pain/Fibromyalgia Agents, Mixed Acting Opioid Analgesics; Opiate Agonists; Opiate Agonists – Abuse Deterrents; Non-Opioid Analgesics; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – Oral• Antihistamines: H1 Blockers – Non-Sedating• Anti-Infective Agents: Aminoglycosides, Inhaled Aminoglycosides; Antivirals, Alpha Interferons, Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products, Anti-hepatitis Agents – Ribavirin, Anti-herpetic Agents, COVID-19, Influenza Agents; Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins; Macrolides; Quinolones, Quinolones – 2nd generation, Quinolones – 3rd Generation; Topical Anti-Infectives, Vaginal• Autonomic Agents: Sympathomimetics, Self-Administered Epinephrine• Biologic Response Modifiers: Immunomodulators, Immunomodulators: Atopic Dermatitis, Targeted Immunomodulator, Colony Stimulating Factors, Immune Globulins; Multiple Sclerosis Agents, Injectable, Oral, Specific Symptomatic Treatment																																	

	<ul style="list-style-type: none"> • Cardiovascular Agents: Antihypertensive Agents, Angiotensin II Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Beta-Blockers, Calcium-Channel Blockers, Vasodilators – Inhaled, Vasodilators - Oral; Antilipemics, Cholesterol Absorption Inhibitors, Fibrin Acid Derivatives, HMG-CoA Reductase Inhibitors (Statins), Niacin Agents, Omega-3 Fatty Acids, PCSK9 Inhibitors; Miscellaneous Heart Failure Agents • Dermatological Agents: Antipsoriatic Agents; Topical Analgesics; Topical Anti-infectives, Impetigo Agents: Topical, Topical Scabicides; Topical Antineoplastics; Topical Steroids, Steroids Topical Low, Steroids Topical Medium, Steroids Topical High, Steroids Topical Very High • Electrolytes and Renal Agents: Phosphate Binding Agents; Potassium-Removing Agents • Gastrointestinal Agents: Antiemetics, Pregnancy-induced Nausea and Vomiting Treatment, Serotonin-receptor Antagonists/Combo; Antiulcer Agents, H2 Blockers, Proton Pump Inhibitors (PPIs); Gastrointestinal Enzymes • Genitourinary Agents: Benign Prostatic Hyperplasia (BPH) Agents, 5-Alpha Reductase Inhibitors, Alpha-Blockers • Hematological Agents: Anticoagulants, Oral, Injectable; Erythropoiesis-Stimulating Agents • Hormones and Hormone Modifiers: Androgens; Antidiabetic Agents, Alpha-Glucosidase Inhibitors/Amylin Analogs/Miscellaneous, Biguanides, Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin, Incretin Mimetics and Combinations, Meglitinides, Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations, Sulfonylureas, Thiazolidinediones and Combinations; Anti-Hypoglycemic Agents; Insulins, Short-Intermediate Acting Insulins, Long-Acting Insulins; Pituitary Hormones, Growth Hormone Modifiers; Progestins for Cachexia; Uterine Disorder Treatment • Monoclonal Antibodies for the Treatment of Respiratory Conditions 	
--	---	--

	<ul style="list-style-type: none"> • Musculoskeletal Agents: Antigout Agents; Bone Resorption Inhibitors, Bisphosphonates, Nasal Calcitonins; Restless Leg Syndrome Agents; Skeletal Muscle Relaxants • Neurological Agents: Alzheimer's Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonist, Barbiturates; Anticonvulsants, Benzodiazepines, Hydantoins; Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Serotonin-Receptor Agonists (Triptans); Antiparkinsonian Agents, Dopamine Precursors, Non-Ergot Dopamine Agonists; Movement Disorders • Ophthalmic Agents: Antiglaucoma Agents; Ophthalmic Antihistamines; Ophthalmic Anti-infectives, Ophthalmic Macrolides, Ophthalmic Quinolones; Ophthalmic Anti-infective/Anti-inflammatory Combinations; Ophthalmic Anti-inflammatory agents, Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Ophthalmics for Dry Eye Disease • Otic Agents: Otic Anti-infectives, Otic Quinolones • Psychotropic Agents: ADHD Agents; Antidepressants, Other, Selective Serotonin Reuptake Inhibitors (SSRIs); Antipsychotics, Atypical Antipsychotics – Long Acting Injectable; Psychostimulants • Respiratory Agents: Nasal Antihistamines; Respiratory Anti-Inflammatory Agents, Leukotriene Receptor Antagonists; Nasal Corticosteroids; Phosphodiesterase Type 4 Inhibitors or Combination; Long-Acting Maintenance Therapy, Inhaled Glucocorticoids, Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products, Long-Acting Beta Adrenergics (LABAs), Anticholinergics and Combination Products; Short-Acting Beta Adrenergics (SABAs), Ipratropium and Combinations • Toxicology Agents: Antidotes, Opiate Antagonists; Substance Abuse Agents • Appendix A: Sickle Cell Disease; HIV Prevention 	
i. Public Comment	Telephonic and web comments were called for, and the phone lines were opened.	

	<p>Public comment was provided by Brett Stevenson, Senior Director of Health Economics and Outcomes Research employed by Arcutis Biotherapeutics.</p> <p>Public comment was provided by Kyle Knudsen, Health Outcomes Liaison at Axon Therapeutics.</p> <p>Public comment was provided by Doctor John Andrews, Physician and Field Medical Director with Pfizer.</p> <p>Public comment was provided by Chris Dube, PharmD within Medical Affairs.</p> <p>Public comment was provided by Rich Oliver, MD, MSL Medical Science Liaison with Liquidia Corporation.</p>	
R. Prime Reports	<p>New Drugs to Market and New Line Extensions</p> <ul style="list-style-type: none"> • Overview of notable FDA decisions expected for third quarter 2025 • Reviewed a new endocrine drug in the drug pipeline: relacorilant • Reviewed a new renal drug in the drug pipeline: sibeprenlimab • Reviewed a new neurology drug in the pipeline: tolebrutinib 	
4. Closing Discussion		
A. Public comments on any subject	No public comments were provided.	
B. Date and location of the next meeting.	<p>Date: December 11, 2025</p> <p>Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109</p>	
C. Adjournment	Chairperson Decerbo adjourned the meeting at 3:55 PM.	

Attachment A – Members of the Public in Attendance

Aaron Feyos	Garrick Wong	Kent Douglas	Reince Rittman
Abraham Meza	Hiten Patadia	Krystal Ngo	Rianna White
Alisa Cadenhead	Jeana Colabianchi	Kyle Knudsen	Richard Junk
Alletha Muzorewa	Jeff Nesheim	Lea Cartwright	Richard Oliver
Amy Hale	Jeffrey Nesheim	Lee Stout	Ryan A Roa
Ann Marie O'Toole	Jenna Doerr	Lisa Glick	Ryan K Bitton
Brad Burris	Jesie MacDonald	Lisa Pulver	Shannon Sturtevant
Brad Harrison	Jill Carroll	Lislie Costalin	Shawn Akey
Brett Stephenson	JJ Roth	Marc Parker	Shelly Nickerson
Cade Grogan	John Andrews	Maria Reyes	Stefanie Abraham
Christina Cobeo	John F	Melbye Rick	Thomas L Beranek
Christine Dube	Juli	Michael Faithe	Todd Dickerson
David Gross	Julie Barbieri	Nora Francis	Tracy L Yarbrough
Dawn Fleming	Justin Clark	Pam Storey	
Fushimi Brent	Justin May	Peeples Herbert	

Attachment B – Submitted Written Comment

None